1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Receptos Acquires Apoptos

M&A Deal Summary

Receptos Acquires Apoptos

On June 26, 2009, Receptos acquired life science company Apoptos

Acquisition Highlights
  • This is Receptos’ 1st transaction in the Life Science sector.
  • This is Receptos’ 1st transaction in the United States.
  • This is Receptos’ 1st transaction in California.

M&A Deal Summary
Date 2009-06-26
Target Apoptos
Sector Life Science
Buyer(s) Receptos
Deal Type Add-on Acquisition

Target

Apoptos

San Diego, California, United States
Apoptos Inc. is focused on developing novel small molecule drug therapies that directly induce tumor cell apoptosis. Using founding technology licensed from Burnham Institute for Medical Research, Fred Hutchinson Cancer Research Center, and Torrey Pines Institute for Molecular Studies, Apoptos is pioneering its anticancer platforms in close collaborations with preeminent scientists in the fields of apoptosis and experimental cancer therapy. Evasion of apoptosis pathways is central to cancer cell survival and reactivation of these cell-death pathways offers attractive anticancer drug development opportunities.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Receptos

San Diego, California, United States
Category Company
Sector Life Science
DESCRIPTION

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. Receptos' lead program, Ozanimod, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune-inflammatory indications including IBD and RMS. Patents supporting Ozanimod were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). Receptos is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for (EoE), an allergic/immune-mediated orphan disease, as well as other pipeline and pre-clinical stage compounds.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2009 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal